Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9480	Companies
185535	Keywords
117927	Articles
99378	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 08/19/2025 at 22:15, 3 months 16 days ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte to provide updates on crofelemer trial results and regulatory pathway at Emerging Growth Conference. Annual meeting results and company strategy also discussed

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference Regulatory Pathway
BRIEF

published on 08/19/2025 at 15:05, 3 months 17 days ago

Napo Pharmaceuticals, filiale de Jaguar Health, sollicite l'avis de la FDA sur le crofelemer pour le traitement d'une maladie pédiatrique rare.

Napo Pharmaceuticals Jaguar Health Réunion De La FDA Traitement MVID Essais Crofelemer
BRIEF

published on 08/19/2025 at 15:05, 3 months 17 days ago

Jaguar Health's Napo Pharmaceuticals Seeks FDA Guidance on Crofelemer for Rare Pediatric Disease

Napo Pharmaceuticals Jaguar Health Crofelemer Trials FDA Meeting MVID Treatment
PRESS RELEASE

published on 08/19/2025 at 15:00, 3 months 17 days ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting
BRIEF

published on 08/14/2025 at 14:05, 3 months 22 days ago

Croissance financière et projets futurs de Jaguar Health au deuxième trimestre 2025

Stratégie Financière Jaguar Health Croissance De Mytesi Chiffre D'affaires Du Deuxième Trimestre 2025 Recherche Sur Crofelemer
BRIEF

published on 08/14/2025 at 14:05, 3 months 22 days ago

Jaguar Health's Q2 2025 Financial Growth and Future Plans

Jaguar Health Financial Strategy Q2 2025 Revenue Mytesi Growth Crofelemer Research
PRESS RELEASE

published on 08/14/2025 at 14:00, 3 months 22 days ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
Jaguar Health, Inc. reports 35% revenue increase in Q2 2025 for prescription & non-prescription products, including license revenue. Mytesi prescription volume up 6.5%. Crofelemer trial yields positive results

Jaguar Health Inc. FDA Meeting Crofelemer Trial Q2 2025 Revenue Mytesi Prescription Volume
BRIEF

published on 08/12/2025 at 15:05, 3 months 24 days ago

Jaguar Health Announces Investor Webcast on August 14, 2025

Financial Results Pharmaceuticals Investor Webcast Jaguar Health Lisa Conte
BRIEF

published on 08/12/2025 at 15:05, 3 months 24 days ago

Jaguar Health annonce un webcast destiné aux investisseurs le 14 août 2025

Résultats Financiers Jaguar Health Lisa Conte Médicaments Webcast Pour Les Investisseurs
PRESS RELEASE

published on 08/12/2025 at 15:00, 3 months 24 days ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on August 14, 2025 to review Q2 financials and corporate updates. CEO Lisa Conte presenting at Emerging Growth Conference on August 20, 2025

Investor Webcast Lisa Conte Emerging Growth Conference Jaguar Health Inc. Q2 Financials

Accesswire

Published on 12/05/2025 at 19:50, 26 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 56 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 31 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 56 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 2 hours 16 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 17 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 1 hour 49 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours 24 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 29 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours 58 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 58 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 5 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 5 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 17 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE